With the potential to transform treatment for severe viral infections, our pipeline sets us on a clear and focused path towards rapid clinical product development and commercialization.

RNA Viruses

To address a variety of infections caused by RNA viruses, we are advancing product candidates that are designed to directly inhibit viral replication by blocking the synthesis of viral RNA. Derived from our nucleotide prodrug platform, these product candidates are designed to have advantageous characteristics and features including: enhanced antiviral activity and selectivity, well tolerated profiles, convenience of once or twice daily oral administration and efficient, scaleable and reproducible manufacturing, as well as long shelf life for potential stockpiling.

SARS-CoV-2

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), colloquially known as the coronavirus, is a positive single-stranded RNA virus that causes the coronavirus disease 2019, known as COVID-19, a highly contagious acute respiratory illness with life-threatening risks for certain patients.

Learn More
Hepatitis C

A blood-borne liver infection, where a substantial unmet medical need remains for short duration and tolerable oral therapy, for large populations of patients, including those with compensated and decompensated cirrhosis, HIV co-infection, and patients at increased risk for adverse events or drug interactions with protease inhibitor-based regimens.

Learn More

Atea’s Advanced Antiviral Pipeline

Atea is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing oral therapies to address the unmet medical needs of patients with serious viral  infections. Currently, Atea is focused on the development of orally-available antiviral agents for serious viral infections, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, and hepatitis C virus (HCV).

Expanded Access Policy